We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
(+31%)
Cap. Flow
-$84M
Cap. Flow
% of AUM
-3.6%
Top 10 Holdings %
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Weyerhaeuser
WY
|
+$59M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$33.1M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$9.18M |
| 4 |
AGN
Allergan plc
AGN
|
+$6.91M |
| 5 |
Plus Therapeutics
PSTV
|
+$6.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$12.1M |
| 2 |
BPTH
Bio-Path Holdings Inc
BPTH
|
+$8.78M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$7.12M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$6.23M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$4.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 9.43% |
| 2 | Real Estate | 2.82% |
| 3 | Energy | 0.36% |
| 4 | Consumer Discretionary | 0.23% |
| 5 | Communication Services | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBST
1
PUT
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $421M | 18.05% |
603
| – | – |
|
2
CALL
Vertex Pharmaceuticals
VRTX
$124B
| $282M | 12.11% |
29,836
+5,836
| +24% | +$409K |
|
3
CALL
Biogen
BIIB
$30.4B
| $110M | 4.72% |
3,488
+1,413
| +68% | +$425K |
|
|
4
PUT
Vertex Pharmaceuticals
VRTX
$124B
| $94.4M | 4.05% |
9,966
+4,040
| +68% | +$283K |
|
|
5
PUT
Teva Pharmaceuticals
TEVA
$36.9B
| $81.6M | 3.5% |
15,574
-7,859
| -34% | -$402K |
|
|
6
PUT
Gilead Sciences
GILD
$167B
| $80.1M | 3.43% |
9,656
-1,510
| -14% | -$118K |
|
7
CALL
AbbVie
ABBV
$465B
| $72.8M | 3.12% |
12,901
+5,366
| +71% | +$282K |
|
|
8
Weyerhaeuser
WY
$17.7B
| $64.6M | 2.77% |
+1,950,977
| New | +$59M |
|
9
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
| $62.1M | 2.66% |
27,474
+787
| +3% | +$16.4K |
|
|
10
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
| $54M | 2.32% |
1,913
+614
| +47% | +$182K |
|
|
11
Teva Pharmaceuticals
TEVA
$36.9B
| $53.1M | 2.28% |
1,013,302
+648,561
| +178% | +$33.1M |
|
12
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $49.5M | 2.12% |
+4,166
| New | +$351K |
|
|
13
PUT
Weyerhaeuser
WY
$17.7B
| $44.7M | 1.92% |
+13,500
| New | +$408K |
|
|
14
CALL
Teva Pharmaceuticals
TEVA
$36.9B
| $36M | 1.54% |
6,870
-8,322
| -55% | -$425K |
|
|
15
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
| $32.9M | 1.41% |
1,166
-50
| -4% | -$14.8K |
|
|
CELG
16
CALL
DELISTED
Celgene Corp
CELG
| $28.1M | 1.2% |
+3,268
| New | +$249K |
|
|
CELG
17
PUT
DELISTED
Celgene Corp
CELG
| $26.8M | 1.15% |
3,126
-962
| -24% | -$73.2K |
|
18
CALL
MannKind Corp
MNKD
$1.21B
| $25.3M | 1.08% |
4,603
+4,096
| +808% | +$164K |
|
19
PUT
Tesla
TSLA
$1.21T
| $23.9M | 1.02% |
+14,925
| New | +$208K |
|
20
PUT
Opko Health
OPK
$1.23B
| $23.2M | 1% |
26,261
+3,034
| +13% | +$26.5K |
|
|
21
PUT
MannKind Corp
MNKD
$1.21B
| $22.2M | 0.95% |
4,035
-187
| -4% | -$7.5K |
|
|
IOC
22
PUT
DELISTED
Interoil Corporation
IOC
| $21.5M | 0.92% |
3,367
+2,472
| +276% | +$158K |
|
|
AGN
23
CALL
DELISTED
Allergan plc
AGN
| $17.3M | 0.74% |
+775
| New | +$160K |
|
|
AGN
24
CALL
DELISTED
Allergan Inc
AGN
| $16.9M | 0.72% |
998
-2,556
| -72% | -$398K |
|
|
AGN
25
PUT
DELISTED
Allergan plc
AGN
| $16.7M | 0.72% |
+750
| New | +$155K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q2 2014 Portfolio in Review
As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.
Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.
- Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
- Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
- Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
- Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
- Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
- Sabby Management opened 83 new positions and closed 65 in Q2 2014.
- Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.
Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.